目的 探讨胆益宁片联合曲匹布通治疗慢性胆囊炎的临床疗效。方法 选取2020年2月—2021年2月在咸阳市第一人民医院诊治的114例慢性胆囊炎患者，依据用药的差距分为对照组和治疗组，每组各57例。对照组口服曲匹布通片，40 mg/次，3次/d；治疗组在对照组基础上口服胆益宁片，0.6 g/次，3次/d。两组患者均治疗2周。观察两组患者临床疗效，比较治疗前后两组患者临床症状缓解时间、胆囊壁厚度、胆囊容积、胆囊收缩功能及血清C反应蛋白（CRP）、白细胞介素6（IL-6）、瘦素（LEP）、核因子κB（NF-κB）和IL-13水平。结果 经治疗，治疗组总有效率显著优于对照组（98.25%vs 82.46%，P<0.05）。经治疗，治疗组症状缓解时间明显早于对照组（P<0.05）。经治疗，两组患者胆囊壁厚度、胆囊容积明显下降，而胆囊收缩功能明显升高（P<0.05），且治疗组改善最显著（P<0.05）。经治疗，两组患者血清CRP、IL-6、LEP、NF-κB水平明显下降，而IL-13明显升高（P<0.05），且治疗组明显好于对照组（P<0.05）。结论 胆益宁片联合曲匹布通片治疗慢性胆囊炎可有效改善患者临床症状，降低机体炎症因子水平，提高患者胆囊功能，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Danyining Tablets combined with trapibutong in treatment of chronic cholecystitis. Methods Patients (114 cases) with chronic cholecystitis in the First People's Hospital of Xianyang from February 2020 to February 2021 were divided into control and treatment groups based on different treatments, and each group had 57 cases. Patients in the control group were po administered with Trepibutone Tablets, 40 mg/time, three times daily. Patients in the treatment group were po administered with Danyining Tablets, 0.6 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the remission time of clinical symptoms, gallbladder wall thickness, gallbladder volume and gallbladder systolic function, and the levels of serum CRP, IL-6, LEP, NF-κB, and IL-13 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly better than that of the control group (98.25% vs 82.46%, P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the gallbladder wall thickness and gallbladder volume in two groups were significantly decreased, while the gallbladder contractile function were significantly improved (P < 0.05), and the treatment group improved most significantly (P < 0.05). After treatment, the levels of serum CRP, IL-6, LEP, and NF-κB in two groups were significantly decreased, while IL-13 was significantly increased (P < 0.05), and the treatment group was significantly better than the control group (P < 0.05). Conclusion Danyining Tablets combined with trapibutong in treatment of chronic cholecystitis can effectively improve the clinical symptoms, reduce the level of inflammatory factors and improve the gallbladder function of patients, which has a certain clinical application value.

R975